1. Home
  2. CTKB vs MEGI Comparison

CTKB vs MEGI Comparison

Compare CTKB & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • MEGI
  • Stock Information
  • Founded
  • CTKB 1990
  • MEGI 2021
  • Country
  • CTKB United States
  • MEGI United States
  • Employees
  • CTKB N/A
  • MEGI N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • MEGI Investment Managers
  • Sector
  • CTKB Health Care
  • MEGI Finance
  • Exchange
  • CTKB Nasdaq
  • MEGI Nasdaq
  • Market Cap
  • CTKB 450.9M
  • MEGI 729.7M
  • IPO Year
  • CTKB 2021
  • MEGI N/A
  • Fundamental
  • Price
  • CTKB $3.45
  • MEGI $14.12
  • Analyst Decision
  • CTKB Hold
  • MEGI
  • Analyst Count
  • CTKB 4
  • MEGI 0
  • Target Price
  • CTKB $6.00
  • MEGI N/A
  • AVG Volume (30 Days)
  • CTKB 1.2M
  • MEGI 178.0K
  • Earning Date
  • CTKB 08-05-2025
  • MEGI 01-01-0001
  • Dividend Yield
  • CTKB N/A
  • MEGI 11.40%
  • EPS Growth
  • CTKB N/A
  • MEGI N/A
  • EPS
  • CTKB N/A
  • MEGI N/A
  • Revenue
  • CTKB $197,050,000.00
  • MEGI N/A
  • Revenue This Year
  • CTKB $0.91
  • MEGI N/A
  • Revenue Next Year
  • CTKB $7.75
  • MEGI N/A
  • P/E Ratio
  • CTKB N/A
  • MEGI N/A
  • Revenue Growth
  • CTKB N/A
  • MEGI N/A
  • 52 Week Low
  • CTKB $2.37
  • MEGI $10.63
  • 52 Week High
  • CTKB $7.63
  • MEGI $14.89
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 52.53
  • MEGI 50.98
  • Support Level
  • CTKB $3.26
  • MEGI $13.95
  • Resistance Level
  • CTKB $3.63
  • MEGI $14.41
  • Average True Range (ATR)
  • CTKB 0.22
  • MEGI 0.20
  • MACD
  • CTKB 0.01
  • MEGI -0.03
  • Stochastic Oscillator
  • CTKB 59.78
  • MEGI 32.08

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund

NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.

Share on Social Networks: